Emcure prices weight-loss drug Poviztra at ₹2,200/week

Emcure Pharmaceuticals launched weight-loss drug Poviztra on Monday under its exclusive partnership with Novo Nordisk.

- Jessica Jani

Emcure is betting on affordability and accessibility to scale the brand as demand for obesity drugs rises.

(BLOOMBERG)

This marks the company’s entry into the fast-growing obesity segment in the country.Poviztra is a semaglutide injection, and comes as a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg. The products are priced competitively, starting at roughly ₹2,200 a week, or ₹8,790 per month, and increasing with the strength of the dosage.

Semaglutide is also sold under brand names Wegovy and Ozempic by Novo Nordisk, with the latter being launched earlier this month at a similar price as Poviztra.

"We are very, very bullish about the price point that we have introduced at roughly ₹2,200 per week of the starting lower dose, which will be allowing for increased affordability and accessibility, we believe, across the country," Vikas Thapar, president - Corporate Development, Strategy and Finance, told Mint in an interview.